Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Initiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platformTopline data expected in the first quarter of 2027SARASOTA, Fla., Sept. 24, 2026 // -- Lakewood-Amedex Biotherapeuti…